875 related articles for article (PubMed ID: 28705927)
21. Imaging features and prognostic value of
Xu T; Zhang X; Zhang S; Liu C; Fu W; Zeng C; Chen Y
BMC Cancer; 2020 Jun; 20(1):596. PubMed ID: 32586285
[TBL] [Abstract][Full Text] [Related]
22. Clinical utility of dual-energy CT used as an add-on to 18F FDG PET/CT in the preoperative staging of resectable NSCLC with suspected single osteolytic metastases.
Wu H; Dong S; Li X; Shi L; Shao D; Zhang Q; Chen M; Cao Y; Thant M; Huang X
Lung Cancer; 2020 Feb; 140():80-86. PubMed ID: 31901595
[TBL] [Abstract][Full Text] [Related]
23. Head-to-head comparison of
Zhang M; Liu Z; Yuan Y; Yang W; Cao X; Ma M; Han B
Diagn Interv Radiol; 2024 Mar; 30(2):99-106. PubMed ID: 38291975
[TBL] [Abstract][Full Text] [Related]
24. Diagnostic impact of integrated 18F-FDG PET/MRI in cerebral staging of patients with non-small cell lung cancer.
Deuschl C; Nensa F; Grueneisen J; Poeppel TD; Sawicki LM; Heusch P; Gramsch C; Mönninghoff C; Quick HH; Forsting M; Umutlu L; Schlamann M
Acta Radiol; 2017 Aug; 58(8):991-996. PubMed ID: 28273734
[TBL] [Abstract][Full Text] [Related]
25. The role of 18F-fluoride PET-CT in the detection of bone metastases in patients with breast, lung and prostate carcinoma: a comparison with FDG PET/CT and 99mTc-MDP bone scan.
Damle NA; Bal C; Bandopadhyaya GP; Kumar L; Kumar P; Malhotra A; Lata S
Jpn J Radiol; 2013 Apr; 31(4):262-9. PubMed ID: 23377765
[TBL] [Abstract][Full Text] [Related]
26. [PET with (18)F-fluorodeoxyglucose for staging of non-small cell lung cancer].
Weber WA; Dietlein M; Hellwig D; Kirsch CM; Schicha H; Schwaiger M
Nuklearmedizin; 2003 Aug; 42(4):135-44. PubMed ID: 12937692
[TBL] [Abstract][Full Text] [Related]
27. Yield of brain 18F-FDG PET in evaluating patients with potentially operable non-small cell lung cancer.
Posther KE; McCall LM; Harpole DH; Reed CE; Putnam JB; Rusch VW; Siegel BA
J Nucl Med; 2006 Oct; 47(10):1607-11. PubMed ID: 17015895
[TBL] [Abstract][Full Text] [Related]
28. The predictive value of
Mattoli MV; Massaccesi M; Castelluccia A; Scolozzi V; Mantini G; Calcagni ML
Radiat Oncol; 2017 Jan; 12(1):4. PubMed ID: 28057034
[TBL] [Abstract][Full Text] [Related]
29. Incidental findings on integrated PET/CT that do not accumulate 18F-FDG.
Bruzzi JF; Truong MT; Marom EM; Mawlawi O; Podoloff DA; Macapinlac HA; Munden RF
AJR Am J Roentgenol; 2006 Oct; 187(4):1116-23. PubMed ID: 16985164
[TBL] [Abstract][Full Text] [Related]
30. [Significance of dual-time-point 18F-FDG PET imaging in evaluation of hilar and mediastinal lymph node metastasis in non-small-cell lung cancer].
Hu M; Yu JM; Liu NB; Liu LP; Guo HB; Yang GR; Zhang PL; Xu XQ
Zhonghua Zhong Liu Za Zhi; 2008 Apr; 30(4):306-9. PubMed ID: 18788639
[TBL] [Abstract][Full Text] [Related]
31. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
[TBL] [Abstract][Full Text] [Related]
32. Brain metastases detectability of routine whole body (18)F-FDG PET and low dose CT scanning in 2502 asymptomatic patients with solid extracranial tumors.
Bochev P; Klisarova A; Kaprelyan A; Chaushev B; Dancheva Z
Hell J Nucl Med; 2012; 15(2):125-9. PubMed ID: 22741148
[TBL] [Abstract][Full Text] [Related]
33. Impact of [18F]FDG-PET on the primary staging of small-cell lung cancer.
Brink I; Schumacher T; Mix M; Ruhland S; Stoelben E; Digel W; Henke M; Ghanem N; Moser E; Nitzsche EU
Eur J Nucl Med Mol Imaging; 2004 Dec; 31(12):1614-20. PubMed ID: 15258700
[TBL] [Abstract][Full Text] [Related]
34. Screening for brain metastases in patients with stage III non-small-cell lung cancer, magnetic resonance imaging or computed tomography? A prospective study.
Schoenmaekers J; Hofman P; Bootsma G; Westenend M; de Booij M; Schreurs W; Houben R; De Ruysscher D; Dingemans AM; Hendriks LEL
Eur J Cancer; 2019 Jul; 115():88-96. PubMed ID: 31129385
[TBL] [Abstract][Full Text] [Related]
35. Comparison of FDG-PET findings of brain metastasis from non-small-cell lung cancer and small-cell lung cancer.
Lee HY; Chung JK; Jeong JM; Lee DS; Kim DG; Jung HW; Lee MC
Ann Nucl Med; 2008 May; 22(4):281-6. PubMed ID: 18535878
[TBL] [Abstract][Full Text] [Related]
36. Role of
Lopez-Lopez V; Robles R; Brusadin R; López Conesa A; Torres J; Perez Flores D; Navarro JL; Gil PJ; Parrilla P
Br J Radiol; 2018 Jan; 91(1081):20170216. PubMed ID: 29034693
[TBL] [Abstract][Full Text] [Related]
37. Clinical significance of incidental [18 F]FDG uptake in the gastrointestinal tract on PET/CT imaging: a retrospective cohort study.
Shmidt E; Nehra V; Lowe V; Oxentenko AS
BMC Gastroenterol; 2016 Oct; 16(1):125. PubMed ID: 27716085
[TBL] [Abstract][Full Text] [Related]
38. Non-small cell lung cancer: prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging.
Shim SS; Lee KS; Kim BT; Chung MJ; Lee EJ; Han J; Choi JY; Kwon OJ; Shim YM; Kim S
Radiology; 2005 Sep; 236(3):1011-9. PubMed ID: 16014441
[TBL] [Abstract][Full Text] [Related]
39. Usefulness 18F-FDG positron emission tomography/computed tomography for detecting recurrence of hepatocellular carcinoma in posttransplant patients.
Kim YK; Lee KW; Cho SY; Han SS; Kim SH; Kim SK; Park SJ
Liver Transpl; 2010 Jun; 16(6):767-72. PubMed ID: 20517911
[TBL] [Abstract][Full Text] [Related]
40. Areas of high 18F-FDG uptake on preradiotherapy PET/CT identify preferential sites of local relapse after chemoradiotherapy for non-small cell lung cancer.
Calais J; Thureau S; Dubray B; Modzelewski R; Thiberville L; Gardin I; Vera P
J Nucl Med; 2015 Feb; 56(2):196-203. PubMed ID: 25572091
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
